ID   IRS1_HUMAN              Reviewed;        1242 AA.
AC   P35568;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 1.
DT   21-MAR-2012, entry version 136.
DE   RecName: Full=Insulin receptor substrate 1;
DE            Short=IRS-1;
GN   Name=IRS1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Skeletal muscle;
RX   MEDLINE=93292738; PubMed=8513971;
RA   Araki E., Sun X.J., Haag B.L. III, Chuang L.M., Zhang Y.,
RA   Yang-Feng T.L., White M.F., Kahn C.R.;
RT   "Human skeletal muscle insulin receptor substrate-1. Characterization
RT   of the cDNA, gene, and chromosomal localization.";
RL   Diabetes 42:1041-1054(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=92181456; PubMed=1311924; DOI=10.1016/0006-291X(92)91640-C;
RA   Nishiyama M., Wands J.R.;
RT   "Cloning and increased expression of an insulin receptor substrate-1-
RT   like gene in human hepatocellular carcinoma.";
RL   Biochem. Biophys. Res. Commun. 183:280-285(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   TURNOVER.
RX   MEDLINE=94059102; PubMed=8240352; DOI=10.1006/bbrc.1993.2315;
RA   Smith L.K., Bradshaw M., Croall D.E., Garner C.W.;
RT   "The insulin receptor substrate (IRS-1) is a PEST protein that is
RT   susceptible to calpain degradation in vitro.";
RL   Biochem. Biophys. Res. Commun. 196:767-772(1993).
RN   [5]
RP   INTERACTION WITH IGF1R.
RX   MEDLINE=95318150; PubMed=7541045; DOI=10.1074/jbc.270.26.15639;
RA   Craparo A., O'Neill T.J., Gustafson T.A.;
RT   "Non-SH2 domains within insulin receptor substrate-1 and SHC mediate
RT   their phosphotyrosine-dependent interaction with the NPEY motif of the
RT   insulin-like growth factor I receptor.";
RL   J. Biol. Chem. 270:15639-15643(1995).
RN   [6]
RP   INTERACTION WITH INSR.
RX   MEDLINE=96007458; PubMed=7559478; DOI=10.1074/jbc.270.40.23258;
RA   He W., O'Neill T.J., Gustafson T.A.;
RT   "Distinct modes of interaction of SHC and insulin receptor substrate-1
RT   with the insulin receptor NPEY region via non-SH2 domains.";
RL   J. Biol. Chem. 270:23258-23262(1995).
RN   [7]
RP   INTERACTION WITH INSR.
RX   PubMed=7537849;
RA   Gustafson T.A., He W., Craparo A., Schaub C.D., O'Neill T.J.;
RT   "Phosphotyrosine-dependent interaction of SHC and insulin receptor
RT   substrate 1 with the NPEY motif of the insulin receptor via a novel
RT   non-SH2 domain.";
RL   Mol. Cell. Biol. 15:2500-2508(1995).
RN   [8]
RP   MUTAGENESIS OF SER-794, AND PHOSPHORYLATION AT SER-794.
RX   MEDLINE=22625648; PubMed=12624099; DOI=10.1074/jbc.M211770200;
RA   Horike N., Takemori H., Katoh Y., Doi J., Min L., Asano T., Sun X.J.,
RA   Yamamoto H., Kasayama S., Muraoka M., Nonaka Y., Okamoto M.;
RT   "Adipose-specific expression, phosphorylation of Ser794 in insulin
RT   receptor substrate-1, and activation in diabetic animals of salt-
RT   inducible kinase-2.";
RL   J. Biol. Chem. 278:18440-18447(2003).
RN   [9]
RP   PHOSPHORYLATION AT SER-1101.
RX   PubMed=15364919; DOI=10.1074/jbc.C400186200;
RA   Li Y., Soos T.J., Li X., Wu J., Degennaro M., Sun X., Littman D.R.,
RA   Birnbaum M.J., Polakiewicz R.D.;
RT   "Protein kinase C Theta inhibits insulin signaling by phosphorylating
RT   IRS1 at Ser(1101).";
RL   J. Biol. Chem. 279:45304-45307(2004).
RN   [10]
RP   PHOSPHORYLATION BY ALK, AND INTERACTION WITH ALK.
RX   PubMed=15226403; DOI=10.1242/jcs.01183;
RA   Motegi A., Fujimoto J., Kotani M., Sakuraba H., Yamamoto T.;
RT   "ALK receptor tyrosine kinase promotes cell growth and neurite
RT   outgrowth.";
RL   J. Cell Sci. 117:3319-3329(2004).
RN   [11]
RP   INTERACTION WITH SOCS7.
RX   PubMed=16127460; DOI=10.1172/JCI23853;
RA   Banks A.S., Li J., McKeag L., Hribal M.L., Kashiwada M., Accili D.,
RA   Rothman P.B.;
RT   "Deletion of SOCS7 leads to enhanced insulin action and enlarged
RT   islets of Langerhans.";
RL   J. Clin. Invest. 115:2462-2471(2005).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-46 AND TYR-662, AND MASS
RP   SPECTROMETRY.
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-629; SER-636 AND
RP   SER-1101, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-46; TYR-612 AND TYR-632,
RP   AND MASS SPECTROMETRY.
RC   TISSUE=Lung carcinoma;
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J.,
RA   Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L.,
RA   Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X.,
RA   Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
RN   [15]
RP   INTERACTION WITH ALK, AND FUNCTION.
RX   PubMed=16878150; DOI=10.1038/sj.onc.1209840;
RA   Kuo A.H., Stoica G.E., Riegel A.T., Wellstein A.;
RT   "Recruitment of insulin receptor substrate-1 and activation of NF-
RT   kappaB essential for midkine growth signaling through anaplastic
RT   lymphoma kinase.";
RL   Oncogene 26:859-869(2007).
RN   [16]
RP   PHOSPHORYLATION AT SER-270; SER-307; SER-636 AND SER-1101.
RX   PubMed=18952604; DOI=10.1074/jbc.M806480200;
RA   Zhang J., Gao Z., Yin J., Quon M.J., Ye J.;
RT   "S6K directly phosphorylates IRS-1 on Ser-270 to promote insulin
RT   resistance in response to TNF-(alpha) signaling through IKK2.";
RL   J. Biol. Chem. 283:35375-35382(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-531 AND SER-1101, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1078, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-632, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Mammary epithelium;
RX   PubMed=19534553; DOI=10.1021/pr900044c;
RA   Heibeck T.H., Ding S.-J., Opresko L.K., Zhao R., Schepmoes A.A.,
RA   Yang F., Tolmachev A.V., Monroe M.E., Camp D.G. II, Smith R.D.,
RA   Wiley H.S., Qian W.-J.;
RT   "An extensive survey of tyrosine phosphorylation revealing new sites
RT   in human mammary epithelial cells.";
RL   J. Proteome Res. 8:3852-3861(2009).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1101, AND MASS
RP   SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-348, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [22]
RP   STRUCTURE BY NMR OF 157-267.
RX   MEDLINE=96185451; PubMed=8599766; DOI=10.1038/nsb0496-388;
RA   Zhou M.-M., Huang B., Olejniczak E.T., Meadows R.P., Shuker S.B.,
RA   Miyazaki M., Trueb T., Shoelson S.E., Fesik S.W.;
RT   "Structural basis for IL-4 receptor phosphopeptide recognition by the
RT   IRS-1 PTB domain.";
RL   Nat. Struct. Biol. 3:388-393(1996).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 4-267.
RX   PubMed=10411883; DOI=10.1073/pnas.96.15.8378;
RA   Dhe-Paganon S., Ottinger E.A., Nolte R.T., Eck M.J., Shoelson S.E.;
RT   "Crystal structure of the pleckstrin homology-phosphotyrosine binding
RT   (PH-PTB) targeting region of insulin receptor substrate 1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:8378-8383(1999).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 889-902 IN COMPLEX WITH
RP   IGF1R.
RX   PubMed=11694888; DOI=10.1038/nsb721;
RA   Favelyukis S., Till J.H., Hubbard S.R., Miller W.T.;
RT   "Structure and autoregulation of the insulin-like growth factor 1
RT   receptor kinase.";
RL   Nat. Struct. Biol. 8:1058-1063(2001).
RN   [25]
RP   VARIANTS PRO-512 AND ARG-971.
RX   MEDLINE=93390176; PubMed=8104271; DOI=10.1016/0140-6736(93)92694-O;
RA   Almind K., Bjoerbaek C., Vestergaard H., Hansen T., Echwald S.,
RA   Pedersen O.;
RT   "Aminoacid polymorphisms of insulin receptor substrate-1 in non-
RT   insulin-dependent diabetes mellitus.";
RL   Lancet 342:828-832(1993).
RN   [26]
RP   VARIANT NIDDM GLY-723 DEL.
RX   MEDLINE=96303710; PubMed=8723689;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:4<364::AID-HUMU13>3.3.CO;2-#;
RA   Esposito D.L., Mammarella S., Ranieri A., della Loggia F., Capani F.,
RA   Consoli A., Mariani-Costantini R., Caramia F.G., Cama A., Battista P.;
RT   "Deletion of Gly723 in the insulin receptor substrate-1 of a patient
RT   with noninsulin-dependent diabetes mellitus.";
RL   Hum. Mutat. 7:364-366(1996).
RN   [27]
RP   VARIANTS NIDDM TYR-1043 AND TYR-1095.
RX   PubMed=10206679;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:5<411::AID-HUMU12>3.3.CO;2-R;
RA   Mammarella S., Creati B., Esposito D.L., Arcuri P., della Loggia F.,
RA   Capani F., Mariani-Costantini R., Caramia F.G., Battista P., Cama A.;
RT   "Novel allele of the insulin receptor substrate-1 bearing two non-
RT   conservative amino acid substitutions in a patient with noninsulin-
RT   dependent diabetes mellitus.";
RL   Hum. Mutat. 11:411-411(1998).
RN   [28]
RP   CHARACTERIZATION OF VARIANT ARG-971.
RX   PubMed=10843189; DOI=10.1210/jc.85.5.2004;
RA   Hribal M.L., Federici M., Porzio O., Lauro D., Borboni P., Accili D.,
RA   Lauro R., Sesti G.;
RT   "The Gly-->Arg(972) amino acid polymorphism in insulin receptor
RT   substrate-1 affects glucose metabolism in skeletal muscle cells.";
RL   J. Clin. Endocrinol. Metab. 85:2004-2013(2000).
RN   [29]
RP   ASSOCIATION OF VARIANT ARG-971 WITH NIDDM.
RX   PubMed=12843189; DOI=10.1210/jc.2002-021716;
RA   Marini M.A., Frontoni S., Mineo D., Bracaglia D., Cardellini M.,
RA   De Nicolais P., Baroni A., D'Alfonso R., Perna M., Lauro D.,
RA   Federici M., Gambardella S., Lauro R., Sesti G.;
RT   "The Arg(972) variant in insulin receptor substrate-1 is associated
RT   with an atherogenic profile in offspring of type 2 diabetic
RT   patients.";
RL   J. Clin. Endocrinol. Metab. 88:3368-3371(2003).
RN   [30]
RP   VARIANT ARG-971.
RX   PubMed=14671192; DOI=10.1210/jc.2003-030453;
RA   Abate N., Carulli L., Cabo-Chan A. Jr., Chandalia M., Snell P.G.,
RA   Grundy S.M.;
RT   "Genetic polymorphism PC-1 K121Q and ethnic susceptibility to insulin
RT   resistance.";
RL   J. Clin. Endocrinol. Metab. 88:5927-5934(2003).
RN   [31]
RP   VARIANT ARG-608, AND CHARACTERIZATION OF VARIANT ARG-608.
RX   PubMed=12679424; DOI=10.1210/jc.2002-020933;
RA   Esposito D.L., Li Y., Vanni C., Mammarella S., Veschi S.,
RA   Della Loggia F., Mariani-Costantini R., Battista P., Quon M.J.,
RA   Cama A.;
RT   "A novel T608R missense mutation in insulin receptor substrate-1
RT   identified in a subject with type 2 diabetes impairs metabolic insulin
RT   signaling.";
RL   J. Clin. Endocrinol. Metab. 88:1468-1475(2003).
RN   [32]
RP   VARIANT ARG-971, AND ASSOCIATION WITH ENDOTHELIAL DYSFUNCTION AND
RP   CARDIOVASCULAR DISEASE.
RX   PubMed=14707024; DOI=10.1161/01.CIR.0000109498.77895.6F;
RA   Federici M., Pandolfi A., De Filippis E.A., Pellegrini G.,
RA   Menghini R., Lauro D., Cardellini M., Romano M., Sesti G., Lauro R.,
RA   Consoli A.;
RT   "G972R IRS-1 variant impairs insulin regulation of endothelial nitric
RT   oxide synthase in cultured human endothelial cells.";
RL   Circulation 109:399-405(2004).
RN   [33]
RP   VARIANT ARG-971, AND MOLECULAR MECHANISM OF LINKAGE TO NIDDM.
RX   PubMed=15590636; DOI=10.1074/jbc.M412300200;
RA   McGettrick A.J., Feener E.P., Kahn C.R.;
RT   "Human insulin receptor substrate-1 (IRS-1) polymorphism G972R causes
RT   IRS-1 to associate with the insulin receptor and inhibit receptor
RT   autophosphorylation.";
RL   J. Biol. Chem. 280:6441-6446(2005).
CC   -!- FUNCTION: May mediate the control of various cellular processes by
CC       insulin. When phosphorylated by the insulin receptor binds
CC       specifically to various cellular proteins containing SH2 domains
CC       such as phosphatidylinositol 3-kinase p85 subunit or GRB2.
CC       Activates phosphatidylinositol 3-kinase when bound to the
CC       regulatory p85 subunit (By similarity).
CC   -!- SUBUNIT: Interacts with UBTF and PIK3CA (By similarity). Interacts
CC       (via phosphorylated YXXM motifs) with PIK3R1 (By similarity).
CC       Interacts with ROCK1 and FER (By similarity). Interacts (via PH
CC       domain) with PHIP (By similarity). Interacts with GRB2 (By
CC       similarity). Interacts with SOCS7. Interacts (via IRS-type PTB
CC       domain) with IGF1R and INSR (via the tyrosine-phosphorylated NPXY
CC       motif). Interacts with ALK.
CC   -!- PTM: Serine phosphorylation of IRS1 is a mechanism for insulin
CC       resistance. Ser-312 phosphorylation inhibits insulin action
CC       through disruption of IRS1 interaction with the insulin receptor
CC       (By similarity).
CC   -!- PTM: Phosphorylation of Tyr-896 is required for GRB2-binding (By
CC       similarity). Phosphorylated by ALK. Phosphorylated at Ser-270,
CC       Ser-307, Ser-636 and Ser-1101 by RPS6KB1; phosphorylation induces
CC       accelerated degradation of IRS1.
CC   -!- POLYMORPHISM: The Arg-971 polymorphism impairs the ability of
CC       insulin to stimulate glucose transport, glucose transporter
CC       translocation, and glycogen synthesis by affecting the
CC       PI3K/AKT1/GSK3 signaling pathway. The polymorphism at Arg-971 may
CC       contribute to the in vivo insulin resistance observed in carriers
CC       of this variant. Arg-971 could contribute to the risk for
CC       atherosclerotic cardiovascular diseases associated with non-
CC       insulin-dependent diabetes mellitus (NIDDM) by producing a cluster
CC       of insulin resistance-related metabolic abnormalities. In insulin-
CC       stimulated human endothelial cells from carriers of the Arg-971
CC       polymorphism, genetic impairment of the IRS1/PI3K/PDPK1/AKT1
CC       insulin signaling cascade results in impaired insulin-stimulated
CC       nitric oxide (NO) release and suggested that this may be a
CC       mechanism through which the Arg-971 polymorphism contributes to
CC       the genetic predisposition to develop endothelial dysfunction and
CC       cardiovascular disease. The Arg-971 polymorphism not only reduces
CC       phosphorylation of the substrate but allows IRS1 to act as an
CC       inhibitor of PI3K, producing global insulin resistance.
CC   -!- DISEASE: Polymorphisms in IRS1 may be involved in the etiology of
CC       non-insulin-dependent diabetes mellitus (NIDDM) [MIM:125853].
CC   -!- SIMILARITY: Contains 1 IRS-type PTB domain.
CC   -!- SIMILARITY: Contains 1 PH domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; S85963; AAB21608.1; -; Genomic_DNA.
DR   EMBL; S62539; AAB27175.1; -; mRNA.
DR   EMBL; BC053895; AAH53895.1; -; mRNA.
DR   IPI; IPI00019471; -.
DR   PIR; I53160; JS0670.
DR   RefSeq; NP_005535.1; NM_005544.2.
DR   UniGene; Hs.471508; -.
DR   PDB; 1IRS; NMR; -; A=157-267.
DR   PDB; 1K3A; X-ray; 2.10 A; B=891-902.
DR   PDB; 1QQG; X-ray; 2.30 A; A/B=4-267.
DR   PDB; 2Z8C; X-ray; 3.25 A; B=731-736.
DR   PDBsum; 1IRS; -.
DR   PDBsum; 1K3A; -.
DR   PDBsum; 1QQG; -.
DR   PDBsum; 2Z8C; -.
DR   ProteinModelPortal; P35568; -.
DR   SMR; P35568; 11-267.
DR   DIP; DIP-523N; -.
DR   IntAct; P35568; 8.
DR   MINT; MINT-149537; -.
DR   STRING; P35568; -.
DR   PhosphoSite; P35568; -.
DR   DMDM; 547738; -.
DR   PRIDE; P35568; -.
DR   DNASU; 3667; -.
DR   Ensembl; ENST00000305123; ENSP00000304895; ENSG00000169047.
DR   GeneID; 3667; -.
DR   KEGG; hsa:3667; -.
DR   UCSC; uc002voh.2; human.
DR   CTD; 3667; -.
DR   GeneCards; GC02M227563; -.
DR   H-InvDB; HIX0024007; -.
DR   HGNC; HGNC:6125; IRS1.
DR   HPA; CAB005261; -.
DR   MIM; 125853; phenotype.
DR   MIM; 147545; gene.
DR   neXtProt; NX_P35568; -.
DR   PharmGKB; PA203; -.
DR   eggNOG; NOG81285; -.
DR   GeneTree; ENSGT00530000063420; -.
DR   HOGENOM; HBG443689; -.
DR   HOVERGEN; HBG000542; -.
DR   InParanoid; P35568; -.
DR   KO; K07187; -.
DR   OMA; GDPKAST; -.
DR   OrthoDB; EOG4J6RQG; -.
DR   PhylomeDB; P35568; -.
DR   Pathway_Interaction_DB; igf1_pathway; IGF1 pathway.
DR   Pathway_Interaction_DB; il2_1pathway; IL2-mediated signaling events.
DR   Pathway_Interaction_DB; il4_2pathway; IL4-mediated signaling events.
DR   Pathway_Interaction_DB; insulin_pathway; Insulin Pathway.
DR   Pathway_Interaction_DB; avb3_integrin_pathway; Integrins in angiogenesis.
DR   Pathway_Interaction_DB; mtor_4pathway; mTOR signaling pathway.
DR   Pathway_Interaction_DB; s1p_s1p2_pathway; S1P2 pathway.
DR   Pathway_Interaction_DB; ptp1bpathway; Signaling events mediated by PTP1B.
DR   Pathway_Interaction_DB; ret_pathway; Signaling events regulated by Ret tyrosine kinase.
DR   Reactome; REACT_111102; Signal Transduction.
DR   Reactome; REACT_6900; Immune System.
DR   NextBio; 14355; -.
DR   PMAP-CutDB; P35568; -.
DR   ArrayExpress; P35568; -.
DR   Bgee; P35568; -.
DR   CleanEx; HS_IRS1; -.
DR   Genevestigator; P35568; -.
DR   GermOnline; ENSG00000169047; Homo sapiens.
DR   GO; GO:0005901; C:caveola; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005899; C:insulin receptor complex; ISS:BHF-UCL.
DR   GO; GO:0005792; C:microsome; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0005158; F:insulin receptor binding; IPI:UniProtKB.
DR   GO; GO:0005159; F:insulin-like growth factor receptor binding; IPI:UniProtKB.
DR   GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; IPI:UniProtKB.
DR   GO; GO:0046934; F:phosphatidylinositol-4,5-bisphosphate 3-kinase activity; TAS:Reactome.
DR   GO; GO:0005080; F:protein kinase C binding; ISS:BHF-UCL.
DR   GO; GO:0042169; F:SH2 domain binding; ISS:UniProtKB.
DR   GO; GO:0005068; F:transmembrane receptor protein tyrosine kinase adaptor activity; ISS:BHF-UCL.
DR   GO; GO:0042593; P:glucose homeostasis; TAS:BHF-UCL.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; IPI:UniProtKB.
DR   GO; GO:0060397; P:JAK-STAT cascade involved in growth hormone signaling pathway; TAS:Reactome.
DR   GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0046676; P:negative regulation of insulin secretion; IDA:BHF-UCL.
DR   GO; GO:0048011; P:nerve growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0014065; P:phosphatidylinositol 3-kinase cascade; IDA:BHF-UCL.
DR   GO; GO:0032000; P:positive regulation of fatty acid beta-oxidation; IMP:BHF-UCL.
DR   GO; GO:0046326; P:positive regulation of glucose import; IMP:BHF-UCL.
DR   GO; GO:0045725; P:positive regulation of glycogen biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0046628; P:positive regulation of insulin receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; ISS:BHF-UCL.
DR   InterPro; IPR002404; Insln_rcpt_S1.
DR   InterPro; IPR011993; PH_like_dom.
DR   InterPro; IPR001849; Pleckstrin_homology.
DR   Gene3D; G3DSA:2.30.29.30; PH_type; 2.
DR   Pfam; PF02174; IRS; 1.
DR   Pfam; PF00169; PH; 1.
DR   PRINTS; PR00628; INSULINRSI.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00310; PTBI; 1.
DR   PROSITE; PS51064; IRS_PTB; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Diabetes mellitus; Disease mutation;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repeat; Transducer.
FT   CHAIN         1   1242       Insulin receptor substrate 1.
FT                                /FTId=PRO_0000084236.
FT   DOMAIN       12    115       PH.
FT   DOMAIN      160    264       IRS-type PTB.
FT   REGION        3    137       Mediates interaction with PHIP (By
FT                                similarity).
FT   REGION      896    898       GRB2-binding (By similarity).
FT   MOTIF       465    468       YXXM motif 1.
FT   MOTIF       551    554       YXXM motif 2.
FT   MOTIF       612    615       YXXM motif 3.
FT   MOTIF       632    635       YXXM motif 4.
FT   MOTIF       662    665       YXXM motif 5.
FT   MOTIF       732    735       YXXM motif 6.
FT   MOTIF       941    944       YXXM motif 7.
FT   MOTIF       989    992       YXXM motif 8.
FT   MOTIF      1012   1015       YXXM motif 9.
FT   COMPBIAS    128    134       Poly-Gly.
FT   COMPBIAS    268    444       Ser-rich.
FT   COMPBIAS    680    686       Poly-Ser.
FT   COMPBIAS    807    815       Poly-Ser.
FT   COMPBIAS    877    882       Poly-Gln.
FT   COMPBIAS   1192   1210       Pro-rich.
FT   MOD_RES       3      3       Phosphoserine (By similarity).
FT   MOD_RES      46     46       Phosphotyrosine.
FT   MOD_RES      99     99       Phosphoserine; by CK2 (By similarity).
FT   MOD_RES     270    270       Phosphoserine; by RPS6KB1.
FT   MOD_RES     307    307       Phosphoserine; by RPS6KB1.
FT   MOD_RES     312    312       Phosphoserine (By similarity).
FT   MOD_RES     329    329       Phosphoserine (By similarity).
FT   MOD_RES     345    345       Phosphoserine (By similarity).
FT   MOD_RES     348    348       Phosphoserine.
FT   MOD_RES     465    465       Phosphotyrosine; by INSR (By similarity).
FT   MOD_RES     531    531       Phosphoserine.
FT   MOD_RES     612    612       Phosphotyrosine; by INSR.
FT   MOD_RES     629    629       Phosphoserine.
FT   MOD_RES     632    632       Phosphotyrosine; by INSR.
FT   MOD_RES     636    636       Phosphoserine; by RPS6KB1.
FT   MOD_RES     662    662       Phosphotyrosine.
FT   MOD_RES     794    794       Phosphoserine; by AMPK and SIK2.
FT   MOD_RES     896    896       Phosphotyrosine; by INSR (By similarity).
FT   MOD_RES     941    941       Phosphotyrosine; by INSR (By similarity).
FT   MOD_RES     989    989       Phosphotyrosine; by INSR (By similarity).
FT   MOD_RES    1078   1078       Phosphoserine.
FT   MOD_RES    1101   1101       Phosphoserine; by RPS6KB1 and PKC/PRKCQ.
FT   MOD_RES    1145   1145       Phosphoserine (By similarity).
FT   MOD_RES    1179   1179       Phosphotyrosine; by INSR (By similarity).
FT   MOD_RES    1223   1223       Phosphoserine (By similarity).
FT   MOD_RES    1229   1229       Phosphotyrosine; by INSR (By similarity).
FT   VARIANT     158    158       P -> R (in dbSNP:rs1801108).
FT                                /FTId=VAR_014853.
FT   VARIANT     209    209       M -> T (in dbSNP:rs1801118).
FT                                /FTId=VAR_014854.
FT   VARIANT     512    512       A -> P (in dbSNP:rs1801276).
FT                                /FTId=VAR_005299.
FT   VARIANT     608    608       T -> R (may contribute to insulin
FT                                resistance by impairing metabolic
FT                                signaling through PI3K-dependent
FT                                pathways).
FT                                /FTId=VAR_025320.
FT   VARIANT     723    723       Missing (in NIDDM).
FT                                /FTId=VAR_005301.
FT   VARIANT     809    809       S -> F (in dbSNP:rs1801120).
FT                                /FTId=VAR_014855.
FT   VARIANT     892    892       S -> G (in dbSNP:rs1801277).
FT                                /FTId=VAR_014856.
FT   VARIANT     971    971       G -> R (in dbSNP:rs1801278).
FT                                /FTId=VAR_005300.
FT   VARIANT    1043   1043       S -> Y (in NIDDM).
FT                                /FTId=VAR_005302.
FT   VARIANT    1095   1095       C -> Y (in NIDDM).
FT                                /FTId=VAR_005303.
FT   VARIANT    1137   1137       D -> N (in dbSNP:rs3731594).
FT                                /FTId=VAR_021837.
FT   MUTAGEN     794    794       S->A: Loss of phosphorylation by SIK2.
FT   CONFLICT    134    134       G -> GG (in Ref. 2; AAB21608).
FT   CONFLICT    362    362       S -> R (in Ref. 2; AAB21608).
FT   CONFLICT    384    384       P -> R (in Ref. 2; AAB21608).
FT   STRAND       13     20
FT   TURN         22     24
FT   STRAND       27     33
FT   TURN         37     39
FT   STRAND       40     49
FT   HELIX        50     54
FT   STRAND       61     65
FT   HELIX        66     68
FT   STRAND       69     75
FT   STRAND       81     90
FT   STRAND       92     96
FT   HELIX       100    113
FT   STRAND      161    172
FT   HELIX       173    176
FT   STRAND      181    187
FT   STRAND      189    196
FT   STRAND      203    207
FT   HELIX       208    210
FT   STRAND      211    217
FT   STRAND      220    225
FT   STRAND      233    239
FT   HELIX       243    258
FT   HELIX       259    261
FT   STRAND      897    901
SQ   SEQUENCE   1242 AA;  131591 MW;  3C0EFD9E32B3E64A CRC64;
     MASPPESDGF SDVRKVGYLR KPKSMHKRFF VLRAASEAGG PARLEYYENE KKWRHKSSAP
     KRSIPLESCF NINKRADSKN KHLVALYTRD EHFAIAADSE AEQDSWYQAL LQLHNRAKGH
     HDGAAALGAG GGGGSCSGSS GLGEAGEDLS YGDVPPGPAF KEVWQVILKP KGLGQTKNLI
     GIYRLCLTSK TISFVKLNSE AAAVVLQLMN IRRCGHSENF FFIEVGRSAV TGPGEFWMQV
     DDSVVAQNMH ETILEAMRAM SDEFRPRSKS QSSSNCSNPI SVPLRRHHLN NPPPSQVGLT
     RRSRTESITA TSPASMVGGK PGSFRVRASS DGEGTMSRPA SVDGSPVSPS TNRTHAHRHR
     GSARLHPPLN HSRSIPMPAS RCSPSATSPV SLSSSSTSGH GSTSDCLFPR RSSASVSGSP
     SDGGFISSDE YGSSPCDFRS SFRSVTPDSL GHTPPARGEE ELSNYICMGG KGPSTLTAPN
     GHYILSRGGN GHRCTPGTGL GTSPALAGDE AASAADLDNR FRKRTHSAGT SPTITHQKTP
     SQSSVASIEE YTEMMPAYPP GGGSGGRLPG HRHSAFVPTR SYPEEGLEMH PLERRGGHHR
     PDSSTLHTDD GYMPMSPGVA PVPSGRKGSG DYMPMSPKSV SAPQQIINPI RRHPQRVDPN
     GYMMMSPSGG CSPDIGGGPS SSSSSSNAVP SGTSYGKLWT NGVGGHHSHV LPHPKPPVES
     SGGKLLPCTG DYMNMSPVGD SNTSSPSDCY YGPEDPQHKP VLSYYSLPRS FKHTQRPGEP
     EEGARHQHLR LSTSSGRLLY AATADDSSSS TSSDSLGGGY CGARLEPSLP HPHHQVLQPH
     LPRKVDTAAQ TNSRLARPTR LSLGDPKAST LPRAREQQQQ QQPLLHPPEP KSPGEYVNIE
     FGSDQSGYLS GPVAFHSSPS VRCPSQLQPA PREEETGTEE YMKMDLGPGR RAAWQESTGV
     EMGRLGPAPP GAASICRPTR AVPSSRGDYM TMQMSCPRQS YVDTSPAAPV SYADMRTGIA
     AEEVSLPRAT MAAASSSSAA SASPTGPQGA AELAAHSSLL GGPQGPGGMS AFTRVNLSPN
     RNQSAKVIRA DPQGCRRRHS SETFSSTPSA TRVGNTVPFG AGAAVGGGGG SSSSSEDVKR
     HSSASFENVW LRPGELGGAP KEPAKLCGAA GGLENGLNYI DLDLVKDFKQ CPQECTPEPQ
     PPPPPPPHQP LGSGESSSTR RSSEDLSAYA SISFQKQPED RQ
//
